Search Results 2261-2270 of 20214 for Receptor
... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...
amplification and wild-type epidermal growth factor receptor (EGFR) with no more than 3 lines of prior therapy (MET Naive), Cohort D: basket of tumor types ...
Androgen receptor pathway inhibitor such as abiraterone, apalutamide, darolutamide, or enzalutamide in the last 2 years. 3.24 Uncontrolled intercurrent non ...
Prior autologous stem cell transplant unless ≥ 3 months after transplant; or prior chimeric antigen receptor T-cell (CAR-T) therapy unless ≥ 3 months ...
The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell ...
Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the ...
Danazol, immunomodulatory imide drugs (IMiDs), luspatercept, or thrombopoietin receptor agonists: 28 days; Cytotoxic chemotherapy: 28 days l. Etanercept: 21 ...
Memantine hydrochloride may enhance cognitive function by binding to and inhibiting channels of receptors located in the central nervous system. Radiation ...
... receptor antibody encephalitis, Progressive multifocal leukoencephalopathy, Autoimmune encephalitis, Meningoencephalitis, Neurosarcoidosis, Myelopathy, Myelitis.
Participants in the clinical trial portion of the study will be randomized to receive a placebo or erenumab, a calcitonin gene-related peptide (CGRP) receptor ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!